Biological diversity reflects an underlying molecular diversity. The molecules found in nature may be regarded as solutions to challenges that have been confronted and overcome during molecular evolution. As our understanding ofthese solutions deepens, the efficiency with which we can discover and/or design new treatments for human disease grows. Nature assists our drug discovery efforts in a variety ofways. Some compounds synthesized by microorganisms and
plants are used directly as drugs. Human genetic variations that predispose to (or protect against) certain diseases may point to important drug targets. Organisms that manipulate molecules within us to their benefit also may help us to recognize key biochemical control points. Drug design efforts are expedited by knowledge of the biochemistry of a target. To supplement this knowledge, we screen compounds from sources selected to maximize molecular diversity. Organisms known to manipulate biochemical pathways of other organisms can be sources of particular interest. By using high throughput assays, pharmaceutical companies can rapidly scan the contents of tens of thousands of extracts of microorganisms, plants, and insects. A screen may be designed to search for compounds that affect the activity of an individual targeted human receptor, enzyme, or ion channel, or the screen might be designed to capture compounds that affect any step in a targeted metabolic or biochemical signaling pathway. While a natural product discovered by such a screen will itself only rarely become a drug (its potency, selectivity, bioavailability, and/or stability may be inadequate), it may suggest a type of structure that would interact with the target, serving as a point of departure for a medicinal chemistry effort-i.e., it may be a "lead." It is still beyond our capability to design, routinely, such lead structures, based simply upon knowledge of the structure of our target. However, if a drug discovery target contains regions of structure homologous to that in other proteins, structures known to interact with those proteins may prove useful as leads for a medicinal chemistry effort. The specificity of a lead for a target may be optimized by directing structural variation to specificity-determining sites and away from those sites required for interaction with conserved features of the targeted protein structure. Strategies that facilitate recognition and exploration of sites at which variation is most likely to generate a novel function increase the efficiency with which useful molecules can be created.
Drug Discovery and Its Relationship to Chemical Ecology
Effective medical treatments are available for many diseases. Recent discoveries include drugs that treat hypertension,
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ulcers, and many bacterial infections (for examples, see ref. 1) . For other devastating diseases, such as diabetes, cancer, AIDS, stroke, and Alzheimer disease, at best only inadequate therapy is available; new approaches to treat these diseases are sought intensively by researchers within the pharmaceutical industry and elsewhere. In the future, new infectious agents may be expected to emerge as important threats, much as human immunodeficiency virus (HIV) has challenged us. Because of the magnitude of these challenges, we continue to seek to improve the strategies by which we discover new drugs.
Most of the effort to create and discover medicinal molecules occurs in the research laboratories of the pharmaceutical industry. Drug discovery demands a coordinated effort among people with diverse talents. Researchers who elucidate disease mechanisms (which point to macromolecules that would make good drug discovery targets) work with those skilled in isolating or synthesizing new molecules and with those who can determine the safety and effectiveness of these molecules. Pharmaceutical company researchers begin the search for clues to the type of molecules that, for example, inhibit a targeted enzyme, by testing diverse structures in their compound collections. These collections consist of compounds synthesized previously in the course of other research programs. Discovery is optimized by scanning as wide a range of structural types as possible (within resource constraints), including compounds found in nature.
Drug discovery has benefited significantly from the study of compounds that organisms have evolved for their own purposes. All of the drugs discovered at the Merck Research Laboratories that became available to patients in the last decade emerged from programs that benefited from knowledge of biological diversity. Some drugs were discovered via natural product screens (2, 3) . Others emerged from medicinal chemistry efforts that drew on knowledge such as how the venom of a Brazilian viper lowers blood pressure (4) (5) (6) . Another program was inspired by a human genetic variation that indicated that a particular enzyme would be a good drug target (7) .
Selection of Drug Discovery Targets
A key step in the process of selecting a molecular target for a drug discovery program involves a demonstration that altering the activity of the proposed target should affect the disease. This is illustrated by the choice of the HIV (9) .
The search for inhibitors of the HIV protease began with compounds that had been prepared during prior work to inhibit related proteases, notably renin, an aspartyl protease involved in blood pressure regulation (9, 10) . While new structures that inhibit the HIV protease have emerged from natural product screens (11, 12) [one structure that inhibits aspartyl proteases, the statine moiety, had been discovered through screening bacterial natural products before the emergence of HIV (10) (9, 13, 14) .
It has proven extraordinarily difficult to obtain an inhibitor of sufficient potency (15) (22) . If this is so, once we understand the biological rationale for assigning a given sensitivity to a given subtype, we will be better able to design drugs for a specific purpose. We would select, from the array of possible conformations of the natural ligand, the appropriate conformation to mimic with our drug.
Drug discovery targets can be suggested by the study of organisms that have evolved the ability to regulate our biochemistry. For example, there is much we can learn from a study of infectious organisms. Parasites and viruses often manipulate key regulatory steps in host defenses (23, 24) . Pathogenic Yersinia, a genus that includes Yersinia pestis, which causes bubonic plague, interferes with the cellular immune response of a mammalian host (25) . The entry of Salmonella into a cell appears to be aided by its use of a leukotriene D4-activated calcium channel that Salmonella activates by triggering host leukotriene D4 synthesis. Salmonella activates leukotriene D4 synthesis via the epidermal growth factor receptor, which activates the mitogen-activated protein kinase, which in turn activates phospholipase A2 (25) . Some viruses have evolved the ability to override cell death programs that otherwise can eliminate virus-infected cells (26, 27) . Shigella flexneri, on the other hand, eliminates our first line of defense against invasion by triggering a cell death program in mammalian macrophages (28) . If we can learn to manipulate key biochemical control points that trigger or block cell death as well as these pathogens do, then we could save neurons in neurodegenerative disease or kill cells in a tumor.
Cyclosporin (originally discovered due to its antifungal activity) and, more recently, FK506 are used clinically to protect against transplant rejection. Elucidation of the biochemical mechanism of action of these microorganism-derived immunosuppressants [complexes of these ligands with the cyclophilins and FK506 binding proteins, respectively, inhibit the calcium/calmodulin-dependent phosphatase calcineurin (29) (30) (31) ] suggested routes to related drug discovery targets. This work highlighted the important role of this phosphatase in immune regulation and in other widespread calciumactivated signaling pathways, ranging from the recovery from cell cycle arrest by a-mating factor in yeast to the opening of an inward potassium channel involved in stomatal opening in plant guard cells (32) . The broader concept of a small molecule acting through complexing large molecules recalls the recognition of antigen bound to histocompatibility molecules by the T-cell receptor (33) .
Other organisms are good sources of agents that selectively block the action of coagulation proteases. Not surprisingly, these include leeches (34) and ticks (35) . The plasminogen activator evolved by vampire bats appears to be even more fibrin-dependent (and, therefore, more clot selective) than that evolved by humans and used clinically (36, 37) .
While the usefulness of anticoagulants and fibrinolytic agents to blood-sucking organisms appears obvious, it is less obvious what the selective advantage of opium alkaloid synthesis is to the poppy plant. Whatever its role in nature, morphine's interaction with the vertebrate central nervous system played an important role in the birth of molecular pharmacology. It led to the identification and isolation of human receptors that bind to opioids and to the identification of endogenous ligands for these receptors (38, 39) . Some organisms provide not drugs or even leads but research tools (18, 40) . For example, a screen can be designed to identify small molecules that block the binding of toxins from spiders, scorpions, or cone snails to ion channels. Potential uses for such small molecule receptor blockers range from limiting the extent of damage after a stroke (41) to treating asthma (42) .
Selecting Sources to Be Screened for Drugs and Leads
If organisms were selected for screening by focusing solely on taxa that had previously yielded interesting structures (43), the potential of as yet unexplored groups of organisms would be missed. Our screens span a broad range of diseases and, therefore, many molecular targets. To increase the chance of finding drugs or at least leads for a medicinal chemistry effort, we gather a diverse array of molecular structures for screens. Molecular diversity is sampled through our chemical collections and by collecting organisms from a broad range of sources. Fungi that live in complex environments and synthesize molecules that regulate the growth of neighboring insects, plants, bacteria, and/or other fungi are likely to be a potentially rich source of leads (44) . A program established to maximize molecular diversity by screening microorganisms from a wide range of phylogenetic and ecological origins, such as endophytic (45) and coprophilic fungi (46) , contributed to the discovery of a new class of metabolites, the zaragozic acids (Fig. 2) , which inhibit the first committed step in the isoprenoid pathway dedicated to sterol biosynthesis in fungi and mammals (48) . Thus, zaragozic acids are broad-spectrum fungicides and also can lower mammalian cholesterol levels. Other interesting fungal metabolites identified by this approach include the antifungal viridofungans (49) , selective nonpeptidyl inhibitors of the antitumor target Ras farnesyl-protein transferase (50) , and an inhibitor of the HIV protease (51) (Fig. 2) .
Plants are another source of molecules with dramatic activity on both invertebrates and vertebrates. Some of these activities may have evolved under selective pressure from foraging animals. For example, plants that produce phytoecdysones can disrupt the development of insects that might devour them. The ecdysone mimic of Cycas, cycasterone, is more potent and less susceptible to metabolic inactivation than a-ecdysone itself (52) . Bruchid beetles have been observed to avoid seeds of the legume Mucuna and may do so because of the high concentrations of L-dopa contained in these seeds (53) . (However, L-dopa, used to treat Parkinson disease, was not originally discovered by following beetle behavior.)
A fungus that grows on wheat expends resources to produce ergot alkaloids, which affect vertebrate monoamine neurotransmission. Do ergot alkaloids have an internal plant/fungus purpose or have they evolved as compounds that protect the plant host and, thus, also the fungus from foraging vertebrates (54)? A plant growth hormone analogue, an insect antifeedant, and a tremorgenic compound that affects sheep and cattle are synthesized by ryegrass when it is infected with the endophyte Acremonium loliae (55) . This may explain the observation that infected ryegrass is taller and more disease-resistant than uninfected ryegrass (56) . However, while plants that resist foragers are potential sources of compounds that interact with human receptors and enzymes, many of these compounds are toxic agents, not drugs. Plants also can be selected for screening based on the advice of indigenous peoples (43, 57) ; for example, knowledge that Desmodium adscendens is used as a medicinal herb in Ghana for treatment of asthma provided a long-sought agonist of the maxi-K channel (58) . This biochemical activity is consistent with this herb's use in other conditions associated with smooth muscle contraction (59) .
Because compounds produced by one species may be modified by another species, knowledge of the natural history of an organism from which a lead was obtained may prove useful to medicinal chemists. For example, a male Danaid butterfly modifies Senecio alkaloids to synthesize pheromones (60); the female pine bark beetle Dendoctonus brevicomus and microorganisms in her gut alter the monoterpenes of the Ponderosa pine (52) . Thus, to assist medicinal chemists in their exploration of how modifications in the structure of the lead affect its activity, ecologists could suggest potential sources of structures derived from the lead. Understanding the biochemical basis of an ecological interaction has the potential to guide us to drugs (61) . For example, the enzyme hydroxymethylglutaryl (HMG)-CoA reductase catalyzes a key step in sterol biosynthesis, the conversion of acetyl-CoA to mevalonate. As mevalonate has been shown to overcome catabolite repression of gibberellin synthesis (62), it seems likely that an inhibitor of HMG-CoA reductase plays a role in regulation of gibberellin synthesis. (Gibberellins, first isolated from the phytopathogenic fungus Gibberella fujikuroi, are plant growth hormones that stimulate stem elongation, induce flowering, and overcome seed dormancy.) Thus, if asked where to look for an inhibitor of HMG-CoA reductase, a chemical ecologist studying gibberellins might have suggested screening such phytopathogenic fungi. [The importance of HMG-CoA reductase inhibition in medicine is demonstrated by lovastatin (2, 63), discovered by random screening of fungi, developed as a drug, and now used by several million people in the United States alone to lower plasma cholesterol (64 The leaf cutter antAtta cephalotes, which cultivates a fungus as food, produces compounds that increase the growth of the fungal food and compounds that block the germination of undesired fungal spores, bacteria, and pollen (52, 65, 66) . This ant avoids leaves of Hymenaea courbaril, which contain a terpenoid harmful to the fungus that the ant cultivates for food (67 Certain compounds appear in nature only when specific organisms interact. For example, the wild tobacco plant Nicotiana sylvestris increases its synthesis of alkaloids when under attack from larvae ofManduca sexta (70) . Pathogens may alter plant gene expression (71) and trigger the synthesis of compounds that help resist pathogen attack (72, 73 (52, 73) . Such a metabolite is missed by routine high throughput screens, which do not evaluate the plant and its fungus together.
In the laboratory, cells from the plant Digitalis lanata do not produce cardiac glycosides unless they differentiate (74) . In the field, the concentration of codeine in the opium poppy varies with the hour of the day (75) . A dramatic example of the influence of the environment on our ability to find potent compounds in an organism is seen with the poison dart frog Phyllobates terribilis. While a lethal dose of the voltagedependent sodium channel agonist batrachotoxin can be harvested by rubbing the tip of a blow dart across the back of a field-caught specimen, batrachotoxin could not be detected in second generation terrarium-reared P. terribilis. Does batrachotoxin, or an essential precursor, come from the frog's diet, and/or is there an environmental trigger of its synthesis (76)? In either case, if the poison arrow frog had been studied only in the laboratory, we would be completely unaware of batrachotoxin. Similarly, if an organism that interacts with one we evaluate becomes extinct, we may miss finding potentially valuable molecules (72, 77 (82) (Fig. 3) . A new science, bioinformatics, is evolving to extract information, with increasing levels of abstraction, from a burgeoning list of DNA sequences (84) . Even otherwise unrelated proteins may have related stretches of amino acid sequence (motifs) (85, 86) and/or similar backbone structure (87) at the binding site. While most computer searches for such motifs focus on the primary sequence of the encoded protein, it is beginning to be feasible to search for homology in the three-dimensional structures that linear sequences can form (84, 86, 89) . While certain of these homologous regions may interact with the same compound [e.g., ATP (85) ], others may interact with structurally homologous but distinct ligands such as individual members of a protein family.
Comparing the sequences of two families of macromolecules that interact, such as DNA sequences and the proteins that recognize them, helps us to perceive the molecular basis of specificity (90) . Variant amino acids that provide an individual sequence's functional specificity are intermixed with consensus amino acids, which provide a motif's structural framework. A compound (whether discovered in a screen or designed by medicinal chemists) that binds to a given sequence in one protein may provide a lead for a compound that can bind to that motif in other proteins. Such information combined with advances in analytical (91) and molecular (92) (83) . This structure confirms the prediction that had been based on the alignment of 11 sequences from a range of species that the conserved leucines (highlighted in yellow) would be oriented toward each other along the faces of neighboring helices. As predicted, the helices cross the DNA in the major goove. Surprisingly, the GCN4 residues making specific DNA base contacts (highlighted in red) are conserved among proteins with different DNA binding specificities, whereas the amino acids contacting the DNA backbone in the GCN4 structure (highlighted in blue) are less conserved in this protein family. Thus, while predictions made based upon linear amino acid sequences from 11 species were confirmed, we await threedimensional structures from diverse sources to elucidate how variant amino acids alter the orientation of the conserved amino acids to effect base-sequence-specific recognition (figure by Tom Ellenberger). dimensional structures, small molecules that interact with the members of a given protein family also may have common underlying three-dimensional structures, which may be viewed as "scaffolds." Specificity of a small molecule for an individual protein family member may be overlayed on a common scaffold by groups that provide specific binding interactions (hydrophobic bonds, salt bridges, hydrogen bonds, etc.). For example, scaffolds designed to interact with an important family of signal transducing molecules, G-protein-linked receptors, provide an approach to a novel set of potentially selective ligands (47) (Fig. 4) . Even when the biological ligand of our target is another protein or peptide, we are beginning to be able to select or design scaffold structures that direct interactions to the right places in space (93, 94 (109) and employing the degeneracy of the genetic code to generate sequence-specific effects on DNA structure (107 (100) . While this or motif can be used as a starting point for combinatorial occurs during the life of an individual, it appears that a similar chemistry. As our ability to carry out combinatorial chemistry process occurs during evolution (98, 99, 101, 102 (103) . Similarly, new serine proteases through combinatorial chemistry and laboratory screening, our appear to have been created by duplication of DNA encoding ability to capture compounds selective for a target protein, a functional serine protease domain, followed by mutation combined with increased understanding of the structure and (104) and attachment of modules with varied functions (105) .
function of conserved and variant regions of protein targets, is Thus, long before the industrial revolution, nature discovered enabling us to evolve more efficient strategies for discovering the efficiency of interchangeable parts (106) . Mechanisms that useful molecules. direct genetic variation away from a useful framework and Learning to Ask Better Questions toward sites where such variation can generate novel functions rather than destroy useful ones are likely to have been A key step in the drug discovery process is the identification evolutionarily selected (107) . For example, after duplication of of a target and demonstration that its activity affects the a serine protease gene, a functional serine protease that is disease process. We can learn to identify key points of biospecific for a new substrate arises through mutations that alter logical regulation by studying the fruits of evolution, such as amino acids located in those regions of the protease that cone snail toxins, vampire bat fibrinolytics, viruses that interdetermine substrate specificity (108 an absolute and not an intrinsic property of the new structure; rather, value depends on the possibilities that the new property generates in the context of other compounds or organisms in the environment in which the activity emerged (116) . Life is challenged by interactions to evolve. Natural selection may favor not only those organisms that produce molecules optimal for their purposes but also those lineages that have evolved the most efficient processes by which to generate optimal pathways and molecules. Molecular mechanisms have evolved that enlist and modify useful structures for new purposes. We are now beginning to search for efficient strategies by which to discover new molecules to protect us against faltering biochemical regulatory mechanisms and evolving infectious agents. The more information we have about the structure of a drug discovery target and its relationship to other proteins, the more efficiently we can optimize potency and selectivity in our drug discovery process. Drug design efforts can begin with a structure that was previously designed or one that was discovered through natural product screening. Combinatorial chemistry will allow us to add rapidly to the rich variety of biologically active molecules that has emerged from molecular evolution.
In the use of natural product screening for drug discovery, our descendants may better understand why a given activity and/or structure can be found in this molecule of this cell of this organism at this stage in its life cycle. A higher level of understanding should emerge from studying many compounds and many organisms in many complex settings. As more species are lost, our biochemical reference library becomes poorer. As we study enough threads and their connections, we can begin to see patterns. These patterns form a framework into which we can place observations and identify gaps in our knowledge. The loss of the shamans' knowledge of the medicinal uses of plants, as their cultures disappear, has been compared to the burning of the library at Alexandria (117) . But 
